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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) causes threatening infection-related mortality worldwide.
Currently, spread of multi-drug resistance (MDR) MRSA limits therapeutic options and requires new approaches to
‘‘druggable’’ target discovery, as well as development of novel MRSA-active antibiotics. RNA polymerase primary s
70
(encoded by gene rpoD) is a highly conserved prokaryotic factor essential for transcription initiation in exponentially
growing cells of diverse S. aureus, implying potential for antisense inhibition.
Methodology/Principal Findings: By synthesizing a serial of cell penetrating peptide conjugated peptide nucleic acids
(PPNAs) based on software predicted parameters and further design optimization, we identified a target sequence (234 to
243 nt) within rpoD mRNA conserved region 3.0 being more sensitive to antisense inhibition. A (KFF)3K peptide conjugated
10-mer complementary PNA (PPNA2332) was developed for potent micromolar-range growth inhibitory effects against four
pathogenic S. aureus strains with different resistance phenotypes, including clinical vancomycin-intermediate resistance S.
aureus and MDR-MRSA isolates. PPNA2332 showed bacteriocidal antisense effect at 3.2 fold of MIC value against MRSA/VISA
Mu50, and its sequence specificity was demonstrated in that PPNA with scrambled PNA sequence (Scr PPNA2332) exhibited
no growth inhibitory effect at higher concentrations. Also, PPNA2332 specifically interferes with rpoD mRNA, inhibiting
translation of its protein product s
70 in a concentration-dependent manner. Full decay of mRNA and suppressed expression
of s
70 were observed for 40 mM or 12.5 mM PPNA2332 treatment, respectively, but not for 40 mM Scr PPNA2332 treatment
in pure culture of MRSA/VISA Mu50 strain. PPNA2332 ($1 mM) essentially cleared lethal MRSA/VISA Mu50 infection in
epithelial cell cultures, and eliminated viable bacterial cells in a time- and concentration- dependent manner, without
showing any apparent toxicity at 10 mM.
Conclusions: The present result suggested that RNAP primary s
70 is a very promising candidate target for developing novel
antisense antibiotic to treat severe MRSA infections.
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Introduction
As a frightening ‘‘superbug’’, methicillin-resistant Staphylococcus
aureus (MRSA) has long been an overwhelming human pathogenic
threat in healthcare-associated infections [1]. Its prevalence and
adaptability in both community and hospital environment makes
healthy patients and immune-deficient patients [2] at high risk of
infection [3,4]. Its continued pathogenicity and virulence [5,6]
causes invasive infection in bloodstream [7], essential organs, and
tissues [8,9], therefore leads to severe clinical presentations and
high mortality rate [4,10]. This is primarily due to the high
incidence of methicillin-resistance that has failed almost all
available antibiotics [11]. Furthermore, there has been an increase
in reports of isolated MRSA strains developing multi-drug or
vancomycin-(intermediate) resistance [12,13], which exacerbated
antibiotic paucity. Interventions like vigilant monitoring of
antibiotic susceptibilities and judicious use of culture-directed
antibiotic agents have been a long-sought endeavor, yielding
limited success [14]. Meanwhile, researchers and pharmaceutical
industry have been driven to discover new MRSA-active agents
(i.e. new chemical derivatives or compounds with new targets [15],
virulence inhibitors [16], natural products, and vaccines [17]) and
combination therapies, resulting in few ideal drugs or solutions
[18]. Thus, antibacterial strategies that provide timely and
effective therapeutic countermeasures are urgently required for
possible outbreaks of MRSA infections. Particularly, specific RNA
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29886silencing in bacteria by antisense antibacterial strategies can
contribute to both aspects of the problem [19].
Antisense antibacterials are short (about 10- to 20- bases),
synthetic DNA analogs that inhibit essential genes expression at
mRNA level in a sequence-specific manner [20]. Thereafter,
antisense inhibition leads to bacteriocidal/bacteriostatic effect or
restoration of bacterial susceptibility, which depends on the
function of targeted gene. Synthetic antisense oligomers, especially
peptide nucleic acid (PNA) [21] and phosphorodiamidate
morpholino (PMO) [22], possess favorable properties in light of
antisense antibacterial application, including improved targeting
specificity, binding affinity, biological stability and access to a
variety of chemical modification. Meanwhile, instead of simple
mixture, cell penetrating peptides (CPP) can be covalently
attached/conjugated at the end of PNA or PMO chain to
enhance cellular uptake of antisense oligodeoxynucelotides (AS-
ODNs) without affecting Waston-Crick base paring between
antisense oligomers and targeted RNAs [23]. Synthetic peptide-
PNA or peptide-PMO conjugates targeting growth-essential genes
have shown to inhibit bacterial growth in pure culture and in
infected tissue culture, Thus, a range of functional genes have been
identified as potential targets [24]. However, only a few early
reports provided preliminary proof-of-principle evidence on
antisense targeting of S. aureus genes for growth inhibitory effect
(i.e. peptide-PNA targeting fabI [25], and phoB,f mhB, gyrA, plus
hmrB [26]) or restoration of antibiotic susceptibility (i.e. liposome-
capsulated phosphorothioate oligodeoxynucleotides targeting mecA
[27]) in pure culture. Targeting resistance mechanism in MRSA
relies on elucidation of subtle intracellular self-regulation among
related genes, the consequences of its antisense inhibition being
too complicated to predict [28]. Thus, identification of growth-
essential genes for more potent antisense inhibition in S. aureus
would aid the development of new anti-MRSA agents [29].
Bacterial DNA-dependent RNA polymerase (RNAP) is a key
enzyme in transcription regulation and gene expression. Its
function requires coordination of a core enzyme (comprising five
subunits a2, b, b9 and v) and an independent s subunit that is
reversibly recruited by core enzyme [30]. The RNAP core
enzyme is responsible for transcription elongation, and different
ss are in charge of transcription initiations from promoters that
express genes in diverse function. The irreversible inhibition of
RNAP thereby causes cell death. This has attracted much
exploration for developing specific RNAP inhibitors (e.g. the
rifamycins with fundamental clinical significance). The most
developed s
70 family of ss, especially the primary s
70,i se s s e n t i a l
for initiating transcription of multiple genes in exponentially
growth cells [31], which to our knowledge has not previously
been demonstrated for antisense target validation in S. aureus.T h e
primary s
70s are unique in structure, function and homology.
The core regions of bacterial and eukaryotic RNAPs share
structural and functional similarities, but the sequences of
encoding genes are only partially homologous. Specifically,
bacterial gene rpoD (encoding the primary s
70 of RNAP) shares
the least homology in sequence with eukaryotic rpoD. Hence, in
contrast to more conserved molecules, sequence-based drugs
targeting rpoD products, including mRNAs, are less likely to cross
react with host molecules. Most importantly, bacterial gene rpoD
is highly conserved in identity and homologous in sequence
among different pathogenic Staphylococcus species [32]. Such
features are distinct advantages for developing narrow-spectrum
anti-MRSA antisense agents [33].
In this study, by using four clinical pathogenic S. aureus genus
with varying resistance patterns (including antibiotic sensitive,
MRSA, MDR-MRSA and VISA), we report the identification of
rpoD as a potent target for markedly bacteriocidal effect in vitro and
ex vivo by antisense peptide-PNA conjugate.
Results
Transcript target site selection
The rpoD gene encoding bacterial RNAP primary s
70 is highly
similar in sequence among S. aureus species. Sequence alignment of
Staphyloccus rpoD by Blast showed 100% gene similarity in S. aureus,
and other Staphyloccus (i.e. ,85% in identity for S. epidermidis, S.
lugdunensis, S. haemolyticus, S. pseudintermedius, and S. saprophyticus,)
(Table 1). Secondary structure of rpoD mRNA (Figure 1) was
predicted by software RNA structure 4.6 and binding parameters
(Table 2) were calculated by Oligo Walk plus PNALIGHT
program. The combined data showed that each conserved region
of rpoD mRNA has highly plausible sub-regions for antisense
targeting. We selected total five plausible target sites for PNA
synthesis (Table 2 & 3). All five mRNA regions are devoid of
obvious stable secondary structures, thus they are theoretically
accessible to complementary PNAs. All PNAs were covalently
conjugated at the carbon terminus with peptide (KFF)3K (in which
K is lysine and F is phenylalanine), acting as a carrier to facilitate
delivery of PNA through stringent S. aureus cell walls [34]. The
efficacy of growth inhibition was determined by measuring
minimal inhibitory concentration (MIC) in liquid bacterial culture.
The results are illustrated for 4 S. aureus strains, including S. aureus
ATCC29213, and clinical isolates of MRSA (i.e., Mu 50, WHO-2
and XIJING) (Table 3). In all strains, PNAs complementary to the
rpoD mRNA nucleotides (nt) encoding 36 to 47, 159 to 170, and
312 to 323 (referring to anti-rpoD PPNA 36, 159 and 312,
respectively) were inactive at the highest concentration tested
(25 mM); PNAs complementary to the rpoD mRNA nucleotides
encoding 123 to 134 (anti-rpoD PPNA123) were equally active to S.
aureus ATCC29213 and MRSA WHO-2, with a MIC value of
25 mM, whereas inactive to MRSA/VISA Mu50 and XIJING;
PNAs complementary to the rpoD mRNA nucleotides encoding
233 to 244 (anti-rpoD PPNA233) were active to all 4 S. aureus
strains, with a MIC value of 12.5, 12.5, 12.5 and 25 mM,
respectively.
Anti-rpoD PPNA optimization
To optimize the design, we synthesized a set of antisense PPNAs
based on anti-rpoD PPNA233 but differed in position of PNA and
CPP, targeting site of PNA, PNA lengths, and CPP type (Table 3).
Such design alterations should help to optimize the antimicrobial
efficacy of obtained anti-rpoD PPNA233, and further illustrate the
feasibility and sensitivity of selected target site in S. aureus rpoD
mRNA. As shown in Table 3, the growth inhibitory effect of anti-
rpoD PPNA2331 was abolished in all 4 S. aureus strains used above;
anti-rpoD PPNA2332 and 2333 were potent, with increased
activity against all 4 S. aureus strains. For anti-rpoD PPNA2332,
the MICs were 12.5 mM, regardless of bacterial resistance
phenotypes. Antisense specificity of anti-rpoD PPNA2332 was
demonstrated in that PPNA with scrambled PNA sequence (Scr
PPNA2332) showed no growth inhibition effect at the highest
concentrations tested (40 and 25 mM, respectively). Anti-rpoD
PPNA2333, which had the same PNA sequence of PPNA2332 but
was attached to a considerably more effective peptide (RXR)4XB
(in which R is arginine, X is 6-aminocaproic acid and B is b-
alanine), showed an equal MIC value of 6.25 mM among 4 S.
aureus strains. However, the peptide-PNAs used in this study can be
membrane active, and membrane permeabilization could result in
nonspecific growth inhibition. This is the exact case for peptide
(RXR)4XB, which showed undesirable growth inhibitory effect on
Antisense Targeting of rpoD in MRSA
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much higher than that of the conjugate PPNA2333
(MIC=6.25 mM), it indicated that only anti-rpoD PPNA 2332
provided improvements and properties that merit further
evaluation.
Bacteriocidal antisense effect of anti-rpoD PPNA2332
The growth inhibitory effect of anti-rpoD PPNA2332 on
bacterial cells were further examined by assessing cell growth
and viability. In pure culture of MRSA Mu 50, we observed a
time- and concentration- dependent inhibition of S. aureus growth
in MH broth with PPNA2332. Scrambled PPNA2332 and control
peptide (KFF)3K did not show any significant growth inhibitory
effect at higher concentrations (Figure 2). There was no
appreciable difference in growth between the cultures incubated
with the Scr PPNA2332 or peptide (KFF)3K and those incubated
without PPNA2332. All cultures grown without PPNA2332
increased by ,4 log after 24 h of growth (1610
5 CFUs/mL at
0 h) (Figure 3). However, PPNA2332 against rpoD mRNA was
bactericidal in culture at $20 mM concentrations, with a .4 log
reduction in CFUs at 24 h, compared with the culture at 0 h
(P,0.01). Full elimination of live bacterial cells was observed for
PPNA2332 at 40 mM when plated undiluted (limit of detection,
10 CFUs/mL). There were no difference in numerated colonies
between all samples from cultures treated with Scr PPNA2332 or
control peptide (KFF)3K and that of growth control. These results
suggested that anti-rpoD PPNA2332 exerts a concentration-
dependent bacteriocidal antisense effect.
Effect of anti-rpoD PPNA2332 on corresponding gene
transcripts and protein expression
The reduction in viable bacterial cells we measured could be
caused by a decay of specific transcripts of gene rpoD through
antisense mechanism and subsequent decreased expression of
protein s
70. To verify this possibility, we performed Reverse
Transcription Polymerase Chain Reaction (RT-PCR) and western
blotting for each individual transcript with total RNA and protein
isolated from 18-hour MRSA/VISA Mu50 cultures upon
inhibition of anti-rpoD PPNA 2332 at different concentrations.
We observed that the levels of rpoD mRNA were greatly
diminished in a concentration-dependent manner in treated
cultures compared with untreated cultures (Figure 4A). Further,
full suppression of rpoD mRNA was observed for PPNA 2332
treatment at 40 mM, which was probably due to steric blockage on
top of mRNA decay effects. The level of the unrelated,
constitutively expressed 16S rRNA gene transcript, assayed as a
control RNA, did not change under any of the culture conditions.
Again, the sequence specificity of the antisense gene knock-down
effect was evaluated in each bacterial culture treated with Scr
PPNA2332, and the expression of rpoD at mRNA level was not
affected by the control condition at doses up to 40 mM (Figure 4A).
Table 1. Homologies of gene rpoD among Staphylococcus species.
Organism GenBank Similarity Identity
Staphylococcus aureus subsp. aureus
Mu50 BA000017.4 100% 100%
Mu3 AP009324.1 100% 100%
T0131 CP002643.1 100% 100%
Str. JKD6008 CP002120.1 100% 100%
TW20 FN433596.1 100% 100%
ED98 CP001781.1 100% 100%
JH1 CP000736.1 100% 100%
NCTC 8325 CP000253.1 100% 100%
USA300_TCH1516 CP000730.1 100% 100%
USA300_FPR3757 CP000255.1 100% 100%
ST398 AM990992.1 100% 100%
MRSA252 BX571856.1 100% 100%
MSSA476 BX571857.1 100% 99%
JKD6159 CP002114.2 100% 99%
ED133 CP001996.1 100% 99%
Other Staphylococcus
Staphylococcus epidermidis RP62A CP000029.1 100% 85%
ATCC 12228 AE015929.1 100% 85%
Staphylococcus lugdunensis HKU09-01 CP001837.1 100% 84%
N920143 FR870271.1 100% 84%
Staphylococcus haemolyticus JCSC1435 AP006716.1 100% 84%
Staphylococcus carnosus subsp. carnosus TM300 AM295250.1 100% 84%
Staphylococcus pseudintermedius ED99 CP002478.1 100% 83%
HKU10-03 CP002439.1 100% 83%
Staphylococcus saprophyticus subsp. saprophyticus ATCC 15305 AP008934.1 98% 83%
doi:10.1371/journal.pone.0029886.t001
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level could lead to decreased expression of its protein product, the
expression of s
70 was tested. Interestingly, inhibiting the rpoD
mRNA by PPNA2332 led to decreased expression of s
70 in a
concentration-dependent manner (Figure 4B). But the Scr
PPNA2332 treatment showed no effect on the expression of s
70.
These results demonstrated that RNAP primary s
70 was crucial
for sustaining bacteria surviving, and knock-down of rpoD by
PPNA2332 induced transcript decay and unsuccessful translation
of transcripts.
Protective effect of anti-rpoD PPNA2332 on human
cultured cells from single MRSA infection
To examine the antibacterial potential of anti-rpoD PPNA2332
in the presence of eukaryotic cells as well as to evaluate its possible
toxicity, we tested it against single clinical MRSA/VISA strain
Mu50 grown in gastric mucosa originated epithelial cell (GEP)
culture medium. In this medium, which is likely to be more
representative of in vivo application, PPNA2332 was .10-fold
more potent (MIC=1 mM) than in MH broth. Furthermore,
epithelial cell cultures were artificially infected with 10
7 CFU/mL
of invasive MRSA/VISA Mu50 cells, and anti-rpoD PPNA2332,
Scr PPNA2332, and control peptide (KFF)3K were added
immediately post-infection or tissue culture medium only. This
system can be viewed as a very simple model for the growth of an
extracellular pathogen in a host. Bacterial CFUs from each
condition were measured at 2, 6, and 24 h after infection. MRSA/
VISA Mu50 grew 2 log in 24 h in the presence of medium alone
(Figure 5). At 2 h after infection, PPNA2332 in infected GEP had
reduced bacterial CFUs by 0.65 log (Figure 5). Further reduction
of CFUs was continued over time, and by 6 h PPNA2332 caused
fully elimination of CFUs, compared with infected GEP without
PPNA treatment. The difference in killing was most pronounced
after 24 h, when there was a 7.45 log difference (P,0.01) in CFUs
between bacterial cells in GEP and the addition of PPNA2332
(Figure 5). The addition of the controls (Scr PPNA or peptide) had
no appreciable effect on antisense killing of bacterial cells,
compared with bacterial cells grown in GEP alone.
Figure 1. Secondary structure of E. coli RNA polymerase primary s
70 mRNA. The target region of the 10-mer peptide nucleic acid
(nucleotides 234–243) is indicated by the bold line.
doi:10.1371/journal.pone.0029886.g001
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cultures, which showed that anti-rpoD PPNA2332 treated GEP
cultures appeared the same as uninfected cultures (Figure 6). All
infected controls appeared the same, independent of treatment,
and showed few GEP cells but massive amounts of bacteria, which
made the cultures appear turbid. Results obtained using Scr
PPNA2332 and peptide (KFF)3K were similar to those obtained in
MRSA/VISA Mu50 cells in GEP culture only (data not shown).
Table 3. MIC of anti-rpoD peptide-PNAs for quality control and clinical strains of Staphyloccus aureus in M-H broth culture.
PNA designation and sequence
a No. of PNA bases MIC
b for S. aureus strains (mM)
ATCC MRSA/VISA/MDR
29213 Mu 50 WHO-2 XIJING
anti-rpoD PPNA (without spacer between PNA and peptide)
36 59-gtcggatcaatt-(KFF)3K-39 12 .25 .25 .25 .25
123 59-agtttttcagca-(KFF)3K- 3 9 12 25 .25 25 .25
159 59-tcatccatttga-(KFF)3K- 3 9 12 .25 .25 .25 .25
233 59-gtttctcgtcag-(KFF)3K-39 12 12.5 12.5 12.5 25
312 59-cgcccaatttct-(KFF)3K- 3 9 12 .25 .25 .25 .25
anti-rpoD PPNA based on 233 (with spacer between PNA and peptide)
2331 59-(KFF)3K-eg
1-ttctcgtca-39 10 .25 .25 .25 .25
2332 59-(KFF)3K-eg
1-tttctcgtca-39 10 12.5 12.5 12.5 12.5
2333 59-(RXR)4XB-eg
1-tttctcgtca-39 10 6.25 6.25 6.25 6.25
Scr 2332 59-(KFF)3K-eg
1-ttttgcccat-39 10 .40 .40 .40 .40
Scr 2333 59-(RXR)4XB-eg
1-ttttgcccat-39 10 .25 .25 .25 .25
Free peptides KFFKFFKFFK .60 .60 .60 .60
RXRRXRRXRRXRXB 30 30 30 30
Controls oxacillin 0.5 .1024 512 .1024
ceftazidine 8 1024 256 .1024
ampicillin 1 .1024 256 .1024
arpoD, RNA polymerase sigma 70; PNA, peptide nucleic acid; PPNA means peptide conjugated PNA; The PNAs are written from their N to their C terminus, and the N
terminus corresponds to the 59 end of a conventional oligonucleotide; ‘‘K’’ indicates lysine, F indicates phenylalanine, ‘‘X’’ indicates 6-aminohexanoic acid, ‘‘B’’ indicates
b-alanine, and eg
1 indicates glycine; Scr means PNA with a scrambled base sequence (as control);
bMinimal inhibitory concentrations (MIC) were the lowest PNA concentrations that prevented bacterial growth by visual inspection after overnight (24 h) growth from
an inoculum of 10
5 CFU/mL. ‘‘VISA’’ is abbreviation for vancomycin-intermediate resistance Staphyloccus aureus; ‘‘MRSA’’ is abbreviation for methicillin-resistant
Staphyloccus aureus; XIJING means clinical MRSA isolate from patients in Fourth Military Medical University affiliated XIJING hospital.
doi:10.1371/journal.pone.0029886.t003
Table 2. Binding parameters predicted by software Oligo walk 5.0 and PNALIGHT.
PNA sequence
Conserved
region of s
70
Target
Site
a Parameters
b
GC
(%)
overall
DG
Duplex
DG
Oligo
-self
DG
Oligo
-oligo
DG Tm(6C)
d
DNA:PNA
59-gtcggatcaatt-39 r1.1 36–47 41.7 216.2 216.6 0 25.2 60.0
59-agtttttcagca-39 r1.2 123–133 33.3 214.5 214.9 0 22.7 56.9
59-tcatccatttga-39 r1.2 159–170 33.3 215.3 215.7 0 22.5 53.4
59-gtttctcgtcag-39 r3 233–244 58.3 217.6 218 0 0 65.1
59-ttctcgtcag-39 r3 233–242 40 —
c —— — 4 3 . 0
59-tttctcgtca-39 r3 234–243 40 — — — — 45.9
59-cgcccaatttct-39 r4 312–323 50 217.8 218.2 0 21.5 57.5
aNumbering from the first base of the gene rpoD;
bDG means free energy; index for each parameter: GC%#60%, overall DG,210 kcal/mol, Duplex DG,225 kcal/mol, oligo-self DG$21.1 kcal/mol, oligo-oligo
DG$28 kcal/mol, Tm.50uC;
c‘‘—’’ means not determined;
dCalculated melting temperature in [uC] of matching PNA/DNA hybrids with no dangling ends.
doi:10.1371/journal.pone.0029886.t002
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Rapid evolution of resistance genes developing among Gram-
positive pathogens has unfortunately exceeded our ability to
develop new antimicrobials [35]. The methicillin-resistance,
vancomycin-intermediate resistance or MDR- S. aureus present
formidable challenges for traditional antibiotic discovery [36].
Novel antisense antibacterial strategies have been introduced and
can efficiently provide potential drugs to combat emerging or re-
emerging pathogens.
The conserved bacterial DNA-dependent RNA Polymerase
(RNAP) is the target of rifamycins and is of great interest as a
potential target for developing antisense bacteriocidal agents.
Thus, we set out to target rpoD (encoding RNAP primary s
70)i nS.
aureus by antisense strategy, assuming it was essential for survival of
pathogenic MRSA. By using peptide-PNA conjugates, our results
suggest that the 234–243 nt of rpoD mRNA (in conserved region 3)
is most sensitive to antisense inhibition. An optimized (RXR)4XB
conjugated PNA complementary to this sequence exerted by far
the most potent (MIC=6.25 mM) antisense growth inhibitory
effect against clinical isolates of pathogenic MRSA in vitro. Our
study also showed that antisense targeting of rpoD by PPNA2332
could significantly inhibit growth of S. aureus genus of different
resistance phenotypes. The effect of PPNA2332 was sequence
specific, because a scrambled-sequence PPNA did not inhibit
growth of S. aureus genus, nor did incubation with the peptide
(KFF)3K alone. In vitro gene-specific bacteriocidal activity was also
seen in clinical isolate of MRSA, which implied that targeting rpoD
by high concentration of PPNA would lead to complete decay of
rpoD mRNA and finally concomitant cell death. More importantly,
micromolar PPNA2332 treatment was able to significantly rescue
100% of MRSA-infected epithelial cells, with full elimination of
MRSA cells in co-culture medium. This highly implied the
therapeutic potential of PPNA2332 in the treatment of MRSA
infections by targeting rpoD.
A challenging aspect of identifying essential genes in bacteria for
antisense inhibition mainly involves efforts to locate the exact
Figure 2. Effects of anti-rpoD PPNA2332 on the growth of
MRSA/VISA Mu50 in pure culture. Anti-rpoD PPNA2332 was added
to cell cultures containing 1.0610
5 CFU/mL MRSA/VISA Mu50 to a final
concentration of 6.25, 12.5, or 25 M. Additional cell cultures were
treated with free MH broth, scrambled PPNA2332 (final concentration of
40 mM), and peptide (KFF)3K (final concentration of 40 mM) in a volume
equal to that of the PPNA2332 preparation as controls. The growth of
different groups of MRSA/VISA Mu50 cells was monitored by using OD
measurements. The data are shown as means for 2 samples from 2
independent tests.
doi:10.1371/journal.pone.0029886.g002
Figure 3. Bacteriocidal effects of anti-rpoD PPNA2332 on the
viable cells of MRSA/VISA Mu50 in pure culture. Anti-rpoD
PPNA2332 was added to cell cultures containing 1.0610
5 CFU/mL
MRSA/VISA Mu50 to a final concentration of 5, 10, 20, or 40 mM.
Additional cell cultures were treated with free MH broth, scrambled
PPNA2332 (final concentration of 40 mM), and peptide (KFF)3K (final
concentration of 40 mM) in a volume equal to that of the PPNA2332
preparation as controls. Aliquots of each culture were collected at 0 h
and 24 h, diluted, and inoculated onto solid MH agar. The number of
CFU was calculated from the number of colonies growing on plates. The
24 h counts for 40 mM PPNA2332 were 0 CFUs/mL. The data are shown
as means 6 SD for 2 samples from 2 independent test. *, P,0.01 for
comparison to control values.
doi:10.1371/journal.pone.0029886.g003
Figure 4. Specific inhibition of RNAP primary s
70 gene
transcript and protein expression by anti-rpoD PPNA 2332.
Triplicate bacterial cultures were grown for 18 h in 100 mL of MH broth
in the presence of anti-rpoD PPNA2332 and scrambled PPNA2332 at
different concentrations with MRSA/VISA Mu50 cells, respectively. The
anti-rpoD PPNA2332 was added once at the start of the growth period.
After 18 h of growth, total RNA and protein was isolated from treated
and untreated cultures. (A) Cellular levels of s
70 RNA were determined
by RT-PCR. The reduction in the amount of RT-PCR product
corresponding to gene rpoD in cells treated with anti-rpoD PPNA2332
at different concentrations was determined as the product specific for
rpoD RNA relative to products for 16S rRNA. (B) Expressions of s
70
protein in different treatment were analyzed by western blotting and
were quantitated densitometrically.
doi:10.1371/journal.pone.0029886.g004
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antisense inhibitory effect of complementary AS-ODNs. Proof-of-
principle evidence from previous study on identifying genes
essential for growth in S. aureus was first offered by Nekhotiaeva
et al [26]. They have used four endogenous genes in S. aureus
RN4220, including phoB (encoding alkaline phosphatase), fmhB
(involved in cell wall biosynthesis), gyrA (involved in DNA
replication), and hmrB (an ortholog of the E. coli acpP gene and
highly sensitive to antisense inhibition in E. coli). And they tested
the bacterial growth inhibition efficacy of antisense peptide-PNAs
to verify the essentiality of these genes. They only designed 2 or 3
peptide-PNAs targeting the start codon region and upstream
Shine-Dalgarno (SD) region in each gene, which were previously
reported for higher sensitivity to antisense inhibition. In all cases,
they observed concentration-dependent growth inhibition with
sequence-specificity. However, MIC values were not determined
and the full-course inhibition of bacterial growth was only
observed for peptide-PNA targeting fmhB at the concentration of
10 mM. Limited information from two other studies have shown
similar MIC values (15 mM) for AS-ODNs targeting fabI [25] or
adk [37] in S. aureus RN4220, regardless of ODN type (i.e., DNA or
PNA) and delivery strategies (i.e., none or peptide mediated).
Bacterial primary s
70s are responsible for transcriptional
initiation of multiple essential genes that play important roles on
cell survival and proliferation in exponential phase. Bacteria have
no bypass mechanism to retrieve the sacrifice for the inactivation
of primary s
70s, which certainly leads to transcription failure and
subsequent loss of functional proteins. Common pathogenic S.
aureus share highly homologous sequences in gene rpoD (Table 1).
However, little evidence has been provided to identify the
accessible and sensitive regions for potent antisense inhibition.
The inhibition profile from our preliminary target site selection
results clearly indicates that the conserved region 3 of rpoD
containing 233 to 244 nt sequence is of most sensitivity among five
selected regions (Table 2&3). More potent growth-inhibition effect
was obtained only for optimized PNA encompassing the 234 to
243 nt sequence, This further confirmed the least indispensable
target sequence for effective antisense inhibition. Notably, the
growth inhibition effect of the 10-mer rpoD-targeting PNA is
through antisense mechanism, which was reflected by the
concentration-dependent decay of rpoD mRNA transcript and
decreased protein expression of s
70 observed for PPNA2332
treated bacterial cells rather than those treated by Scr PPNA2332.
Certain peptide-PNA and peptide-PMO oligomers targeting
growth-essential genes are more bacteriocidal in vitro relative to
molar or mass equivalent doses of ampicillin and rifampicin, and
they act with gene and sequence selectivity. Potent bacteriocidal
antisense effect of anti-rpoD PPNA2332 was highly presumable to
resemble pharmacological aspects (or mode of action) of
rifampicins, the famous broad-spectrum RNAP inhibitors that
accumulate in bacterial cells to exert post antibiotic effect, with
comparatively higher MICs than other types of antibiotics [38].
Figure 5. Protective effect of anti-rpoD PPNA2332 on epithelial
cell culture infected with noninvasive single MRSA/VISA Mu50
infection. The symbols represent time points of cell harvest (2, 6, and
24 h) and are displayed as the mean number of colony-forming units
(CFUs) per milliliter. Error bar represents SD. The 6 h counts for 1 mM
PPNA2332 were 0 CFUs/mL. For all observations in co-cultures
(GEP+MRSA/VISA Mu50) treated, with the limit of detection indicated
as 10 CFUs/mL. Scr PPNA2332, Scrambled sequence control PPNA2332;
GEP, gastric mucosa originated epithelial cell.
doi:10.1371/journal.pone.0029886.g005
Figure 6. Light micrographs of epithelial cell cultures. The
images show epithelial cell cultures grown in DMEM/HIGH Glucose,
10% FCS. The column at left shows epithelial cell cultures without
added MRSA/VISA Mu50; the right column shows epithelial cell cultures
that were inoculated with MRSA/VISA Mu50. The top panels of each
column show cultures not treated with PPNA, and the rows below show
cultures treated with increasing amounts of anti-rpoD PPNA2332 (1, 5,
and 10 mM). Magnification, 6100.
doi:10.1371/journal.pone.0029886.g006
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enhance antibacterial potency and expand antibacterial spectrum
[39]. The mechanism of uptake for such peptides and their
capacity to deliver cargo molecules into cells are controversial, and
there is evidence for both energy-dependent and energy-
independent mechanisms [40]. Also, the uptake properties are
affected by the nature of the cargo molecule. Despite these
difficulties, carrier peptides appear to be one of the few options
available to significantly improve effects of antisense agents in a
variety of different applications. The peptide (RXR)4XB used in
this study was previously reported as a more potent permeabilizer
against E. coli cells than the (KFF)3K peptide [41,42]. Our results
suggested the (RXR)4XB peptide mediated more efficient delivery
for clinical MRSA isolates than the (KFF)3K peptide, because
lower MIC values were observed for (RXR)4XB conjugated PNA.
However, (RXR)4XB itself showed growth inhibition effect at the
concentration of 30 mM in pure culture of MRSA, indicating a
small safety window. Therefore, improved peptide carriers are
needed if antisense PNAs are to have broad medical applications
against MRSA.
Antimicrobials can demonstrate potency in vitro and then fail in
cell culture models or in vivo studies. We used isolated GEP from
human donors to determine whether the addition of PPNA2332
could kill co-cultured MRSA ex vivo and protect human cells from
lesion and death. Interestingly, more potent bacteriocidal antisense
effect of PPNA2332 was demonstrated by the increase of CFUs in
no treatment control cultures and the full elimination of CFUs in
PPNA2332 treated culture at 24 h. This is probably due to the
lower growth rate of bacterial cells in DMEM than that in MH
broth. However, accumulation and sustained bacteriocidal effect
of PPNAs were observed to eliminate bacteria dramatically in a
time- and concentration- dependent manner with no obvious cell
toxicity. Most importantly, Scr PPNA2332 showed no bacterio-
cidal effect, which indicated its gene-specific antisense effect in a
co-cultured medium. Meanwhile, the (KFF)3K peptide itself
exerted no growth inhibitory effect at higher concentrations in
co-culture with mammalian cells, which showed the antibacterial
effect of PPNA2332 was antisense mediated only.
Important challenges remain for the application of antisense
technology to the treatment of gram-positive pathogens. Clearly,
many issues concerning the in vivo activity, general bioavailability,
animal and human toxicity, and pharmacokinetic behavior of
peptide-PNA conjugates still need to be addressed. In this work,
we firstly demonstrate that bacterial rpoD encoding RNAP primary
s
70 is essential for S. aureus growth and is a highly promising target
for developing specific antisense therapeutic agents like peptide-
PNA conjugates.
Materials and Methods
Chemicals
All antibiotics used were purchased from the National Institute
for the Control of Pharmaceutical and Biological Products
(Beijing, China). All other chemicals and solvents were of
analytical grade.
Bacterial strains, CPP, and PNA
The S. aureus strain ATCC29213 (antibiotic sensitive, for quality
control) and WHO-2 (MRSA) were obtained from the Chinese
National Center for Surveillance of Antimicrobial Resistance
(Beijing, China), and clinical strain MRSA XIJING (MDR) was
isolated from cultures of sputum or catheter samples from patients
in Xijing Hospital (Xi’an, China). MRSA/VISA Mu50
(ATCC700699) was purchased from MicroBiologics (Minnesota,
USA). All strains expressed rpoD, which was confirmed by PCR
detection (data not shown). CPPs were synthesized and purified at
Genotide, Inc. (Xi’an, Shannxi, China). PNAs were synthesized
and purified at Panagene, Inc (DAEHEON, Korea). peptide-
conjugated PNAs were synthesized by manual coupling chemistry
and purified at Panagene, Inc (DAEHEON, Korea), with the base
and amino acid sequences shown in Table 3.
PNA target site selection and anti-rpoD peptide-PNA
(PPNA) optimization
Sequence alignment of gene rpoD was performed to decide the
region that showed the highest sequential homology among
different S. aueus species. Secondary structure of rpoD mRNA
predicted by RNA structure 4.6 software. DNA:RNA and
DNA:PNA paring parameters referenced by Oligo Walk 5.0 and
PNALIGHT program were used to decide the site that showed
best binding affinity. Building from evidence that 12-base antisense
PNAs was an effective length [23], five plausible target sites located
in the region that satisfied both above aspects were chosen for
synthesis of complementary antisense PNAs at 12-base length.
Effective target site in rpoD was verified by modified MIC test of
PPNA in four S. aureus strains with different characteristics in
resistance phenotype. All PNAs used are covalently conjugated
with the same cell penetrating peptide (KFF)3K at the carbon
terminus (corresponding to the 39 end of a conventional
oligonucleotide).
To further optimize the anti-rpoD PPNA that showed best
antisense inhibitory efficacy in preliminary target site selection, de
novo design in ways of (i) adding glycine spacer between PNA and
CPP; (ii) shortening PNA length; and (iii) utilization of newly
developed CPP (RXR)4XB for more efficient PNA delivery into
larger scale of bacterial species, were performed. Optimal anti-
rpoD PPNA was selected by minimal inhibitory concentration
(MIC) results determined for clinical isolates of pathogenic S. aureus
species.
Bacterial growth assay and susceptibility testing
MICs were determined twice by the microdilution assay in
sterilized 96-well polypropylene microtiter plates according to the
broth microdilution guideline based on Good et al. [23]. Briefly,
single colony overnight culture of subjected bacterial cells was
diluted to give a final inoculation at 10
5 CFU/mL in duplicate
100 mL Mueller Hinton (MH) broth in a low-binding 96-well
microtiter plate. Stocks of PPNA, Scr PPNA and CPPs were added
immediately to the indicated final concentrations. Plates were
incubated at 35uC in aerobic environment for 24 h of overnight
culture. MICs were the lowest PNA concentrations that prevented
bacterial growth by visual inspection after overnight (24 h) growth.
To verify the specific antisense effect, peptide was also conjugated
to a scrambled PNA with a base sequence that was not
complementary to the selected target site of rpoD mRNA. To
control for nonspecific toxicity, the MIC of the control CPPs
(KFF)3K and (RXR)4XB in all cases, was above the limit of
measurement, which was 60 or 30 mM.
To determine the growth curve for MRSA/VISA Mu50 in the
broth medium, cells were diluted and mixed with no PPNA, anti-
rpoD PPNA2332 (6.25, 12.5, and 25 mM), and scrambled
PPNA2332 (40 mM). The growth rate of the cells was monitored
by measuring the OD values at 620 nm with a microplate reader
(Bio-Rad Laboratories, Tokyo, Japan) at different time points (0, 2,
4, 6, 8, 10, 12, 14, 16, 18, and 24 h). After 24 h culture, viable cells
were determined by plating 50 mL samples from each wells onto
Mueller-Hinton agar plates in appropriate diluted concentrations,
and numbers of colonies was counted.
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To compare s
70 RNA levels in inhibited and uninhibited
bacterial cells, duplicate subjected MRSA/VISA Mu50 were
grown as described above and treated with either no PPNA
inhibitor, different concentrations of anti-rpoD PPNA2332, or
scrambled PPNA2332 for 18 h. Cell amounts were verified by
plating. Total RNA from each culture was prepared using the
RNeasy Mini Kit (QIAGEN China Co. Ltd, Shanghai, China) or
RNAprep pure Cell/Bacteria Kit (TIANGEN BIOTECH Co.
Ltd, Beijing, China), and followed by reverse transcript using
PrimeScript RT reagent Kit with DNA Eraser (TAKARA BIO
INC, Kyoto, Japan). PCR was performed with the Premix Taq
RT-PCR System (TAKARA BIO INC, Kyoto, Japan) according
to the manufacturer’s instructions. Primers specific for rpoD gene in
subjected S. aureus were listed as followed. Primers specific for
MRSA/VISA Mu50 rpoD were 59- CAGATACTGACGAGAAA
-39 and 59- GAATAACATACCACGAC-39. Primers specific for
MRSA/VISA Mu50 16S rRNA were 59- CGTGGATAACC-
TACCTATAAGACT-3 and 59-GATTCCCTACTGCTGC-
CTC-39. The PCR fragment encompasses the targeting site of
PPNA2332 in rpoD gene. Amplification was performed in a
Gradient thermal cycler (BioRad laboratories Inc., Hercules, CA,
USA) under the following condition: denaturation at 95uC for
3 min for the first cycle and for 30 s thereafter, annealing at 55uC
for 30 s, and extension at 72uC for 40 s for 32 repetitive cycles.
Final extension was at 72uC for 10 min. 16S rRNA was used as an
internal control. The PCR products were analyzed by electro-
phoresis on a 1% agarose gel.
Western blotting
To compare s
70 expression levels in inhibited and uninhibited
bacterial cells, duplicate subjected MRSA/VISA Mu50 were
grown as described above and treated with either no PPNA
inhibitor, different concentrations of anti-rpoD PPNA2332 and
scrambled PPNA2332 for 18 h. Anti-rpoD PPNA treated bacterial
cells and untreated controls were lysed using lysis buffer (Dingguo
Biotech Co, Ltd, Beijing, China) containing lysozyme (100 g/mL)
and PMSF (1 mM). Cell lysates were quantitated, resolved, blotted
and visualized essentially as previously described. Equal amounts
of protein were loaded and separated on 12% SDS-polyacryl-
amide gel and were then transferred to polyvinylidene difluoride
membranes (Millipore Corporation, Billerica, MA, USA). The
bacterial RNAP s
70 monoclonal antibody (Abcam, Cambridge,
MA, USA) was used at dilution of 1:1000 for overnight blotting at
4uC; the secondary horseradish peroxidase-conjugated anti-mouse
antibody was used at dilution of 1:2000.
Epithelial cell culture, single bacterial infection, and anti-
rpoD PPNA2332 treatment
Epithelial cells (gastric mucosa originated, a gift from Dr. Na
Chai) were plated in 96-well culture dishes (Falcon, Franklin
Lakes, NJ) at a concentration of 1.5610
4 cells/mL in a volume of
200 mL and grown at 37uC for 48 h in Dulbecco’s minimal
essential medium (high sugar DMEM, HyClone, Logan, Utah)
supplemented with 10% fetal bovine serum (HyClone, Logan,
Utah) in 95% air-5% CO2. An overnight respective culture of
MRSA/VISA Mu50 (ATCC 700699) was diluted by high sugar
DMEM with 10% fetal bovine serum for fixed-concentration
experiments, and transferred to wells containing epithelial cells.
The starting bacterial inoculum for single infection was
1610
7 CFU/mL in a 100 mL volume. Anti-rpoD PPNA 2332 (1,
5, and 10 mM) and scrambled PPNA2332 (20 mM) were
immediately added, and the cultures were incubated at 37uCi n
95% air-5% CO2 for 24 h. After 24 h, cultures were examined
and photographed with a Nikon inverted light microscope under
6100 magnification. And culture supernatant was removed,
diluted to appropriated concentration and plated on MH agar
to measure viable bacterial cells.
Statistical Analysis
Values shown in the graph are means of two or three replicates
from independent experiments. Results are expressed as mean or
mean 6 SD where indicated. For the in vitro experiments, cell
viability (in units of CFUs per milliliter) at 24 h was calculated for
MRSA/VISA Mu50 and PPNA2332 treatment condition,
including no treatment. The difference (in units of log count
+0.5) between cultures treated with PPNA2332 and untreated
cultures was analyzed by means of the paired Student t test. Values
were linearly transformed by the addition of a constant, 0.5, to
allow statistical testing of the log counts, as samples were
completely sterilized by PPNA2332 (i.e., 0 CFUs/mL). A
probability value of P,0.01 was considered indicative of statistical
significance.
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